CIAM
SAGE

Caitong International Asset Management’s Sage Therapeutics SAGE Stock Holding History

Caitong International Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,864
Closed -$17K – 2440
2025
Q2 		$17K Buy
1,864
+1,489
+397% +$11K 0.01% 553
2025
Q1 		$2.98K Buy
+375
New +$2.75K ﹤0.01% 1194

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Caitong International Asset Management's SAGE Position: Q3 2025 in Review

Caitong International Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,864 shares — an estimated $17K sold.

Caitong International Asset Management first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $17K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Caitong International Asset Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 1,864 Sage Therapeutics shares in Q3 2025, an estimated $17K.
  • Caitong International Asset Management first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
  • Caitong International Asset Management's Sage Therapeutics position peaked at $17K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Caitong International Asset Management's 13F filing for Q3 2025, filed 19 Nov 2025.